| __timestamp | Amneal Pharmaceuticals, Inc. | Soleno Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 84615000 | 2917513 |
| Thursday, January 1, 2015 | 109679000 | 7878291 |
| Friday, January 1, 2016 | 118757000 | 8366794 |
| Sunday, January 1, 2017 | 109046000 | 6610381 |
| Monday, January 1, 2018 | 230435000 | 6556000 |
| Tuesday, January 1, 2019 | 289598000 | 6930000 |
| Wednesday, January 1, 2020 | 326727000 | 8758000 |
| Friday, January 1, 2021 | 365504000 | 10806000 |
| Saturday, January 1, 2022 | 399700000 | 9844000 |
| Sunday, January 1, 2023 | 429675000 | 13481000 |
Infusing magic into the data realm
In the competitive landscape of pharmaceuticals, understanding financial trends is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Amneal Pharmaceuticals, Inc. and Soleno Therapeutics, Inc. from 2014 to 2023. Amneal Pharmaceuticals, a major player, has seen its SG&A expenses grow significantly, peaking at approximately 430 million in 2023, a fivefold increase from 2014. This reflects their aggressive expansion and market penetration strategies.
Conversely, Soleno Therapeutics, a smaller entity, has maintained a more modest growth in SG&A expenses, reaching around 13 million in 2023. This steady increase, about 4.6 times from 2014, indicates a cautious yet consistent approach to scaling operations. The stark contrast in these financial trajectories highlights the diverse strategies within the pharmaceutical industry, offering insights into how companies allocate resources to drive growth and innovation.
Breaking Down SG&A Expenses: Sanofi vs Amneal Pharmaceuticals, Inc.
Vertex Pharmaceuticals Incorporated and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Summit Therapeutics Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs Amneal Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Soleno Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Ascendis Pharma A/S or Amneal Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Cytokinetics, Incorporated and Soleno Therapeutics, Inc.
Breaking Down SG&A Expenses: Amneal Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Amneal Pharmaceuticals, Inc. and MiMedx Group, Inc.
Cost Management Insights: SG&A Expenses for Viking Therapeutics, Inc. and Soleno Therapeutics, Inc.
Merus N.V. vs Soleno Therapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for HUTCHMED (China) Limited and Soleno Therapeutics, Inc.